Patents Represented by Attorney Len S. Smith
-
Patent number: 8299109Abstract: Pharmaceutical formulations and methods for the topical or transdermal delivery of 1-isobutyl-1H-imidazo[4,5-c]-quinolin-4-amine or 1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine, i.e., imiquimod, to treat actinic keratosis with short durations of therapy, than currently prescribed for the commercially available ALDARA 5% imiquimod cream, as now approved by the U.S. Food & Drug Administration (“FDA”), are disclosed and described. More specifically, lower dosage strength imiquimod formulations to deliver an efficacious dose of imiquimod for treating actinic keratosis with an acceptable safety profile and dosing regimens that are short and more convenient for patient use than the dosing regimen currently approved by the U.S. Food & Drug Administration (“FDA”) for ALDARA 5% imiquimod cream to treat actinic keratosis are also disclosed and described.Type: GrantFiled: July 13, 2011Date of Patent: October 30, 2012Assignee: Medicis Pharmaceutical CorporationInventors: Michael T. Nordsiek, Sharon F. Levy, James H. Lee, James H. Kulp, Kodumudi S. Balaji, Tze-Chiang Meng, Jason J. Wu, Valyn S. Bahm, Robert Babilon
-
Patent number: 8242155Abstract: Pharmaceutical formulations and methods for the topical or transdermal delivery of 1-isobutyl-1H-imidazo[4,5-c]-quinolin-4-amine or 1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine, i.e., imiquimod, to treat actinic keratosis with short durations of therapy, than currently prescribed for the commercially available ALDARA 5% imiquimod cream, as now approved by the U.S. Food & Drug Administration (“FDA”), are disclosed and described. More specifically, lower dosage strength imiquimod formulations to deliver an efficacious dose of imiquimod for treating actinic keratosis with an acceptable safety profile and dosing regimens that are short and more convenient for patient use than the dosing regimen currently approved by the U.S. Food & Drug Administration (“FDA”) for ALDARA 5% imiquimod cream to treat actinic keratosis are also disclosed and described.Type: GrantFiled: July 13, 2011Date of Patent: August 14, 2012Assignee: Medicis Pharmaceutical CorporationInventors: Michael T. Nordsiek, Sharon F. Levy, James H. Lee, James H. Kulp, Kodumudi S. Balaji, Tze-Chiang Meng, Jason J. Wu, Valyn S. Bahm, Robert Babilon
-
Patent number: 8242286Abstract: The present invention is directed to the compound 2-(4-(hydroxymethyl)phenoxy)-1-(3-(2-(trifluoromethyl)phenoxy)pyrrolidin-1-yl)ethanone, its use as an inhibitor of stearoyl CoA desaturase and to pharmaceutical compositions containing this compound.Type: GrantFiled: July 28, 2008Date of Patent: August 14, 2012Assignee: Medicis Pharmaceutical CorporationInventors: Jin Li, Nicole Lee Kolosko
-
Patent number: 8236816Abstract: Pharmaceutical formulations and methods for the topical or transdermal delivery of 1-isobutyl-1H-imidazo[4,5-c]-quinolin-4-amine or 1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine, i.e., imiquimod, to treat actinic keratosis with short durations of therapy, than currently prescribed for the commercially available ALDARA 5% imiquimod cream, as now approved by the U.S. Food & Drug Administration (“FDA”), are disclosed and described. More specifically, lower dosage strength imiquimod formulations to deliver an efficacious dose of imiquimod for treating actinic keratosis with an acceptable safety profile and dosing regimens that are short and more convenient for patient use than the dosing regimen currently approved by the U.S. Food & Drug Administration (“FDA”) for ALDARA 5% imiquimod cream to treat actinic keratosis are also disclosed and described.Type: GrantFiled: July 12, 2011Date of Patent: August 7, 2012Assignee: Medicis Pharmaceutical CorporationInventors: Michael T. Nordsiek, Sharon F. Levy, James H. Lee, James H. Kulp, Kodumudi S. Balaji, Tze-Chiang Meng, Jason J. Wu, Valyn S. Bahm, Robert Babilon
-
Patent number: 8222270Abstract: Pharmaceutical formulations and methods for the topical or transdermal delivery of 1-isobutyl-1H-imidazo[4,5-c]-quinolin-4-amine or 1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine, i.e., imiquimod, to treat actinic keratosis with short durations of therapy, than currently prescribed for the commercially available ALDARA 5% imiquimod cream, as now approved by the U.S. Food & Drug Administration (“FDA”), are disclosed and described. More specifically, lower dosage strength imiquimod formulations to deliver an efficacious dose of imiquimod for treating actinic keratosis with an acceptable safety profile and dosing regimens that are short and more convenient for patient use than the dosing regimen currently approved by the U.S. Food & Drug Administration (“FDA”) for ALDARA 5% imiquimod cream to treat actinic keratosis are also disclosed and described.Type: GrantFiled: July 8, 2011Date of Patent: July 17, 2012Assignee: Medicis Pharmaceutical CorporationInventors: Michael T. Nordsiek, Sharon F. Levy, James H. Lee, James H. Kulp, Kodumudi S. Balaji, Tze-Chiang Meng, Jason J. Wu, Valyn S. Bahm, Robert Babilon
-
Patent number: 7432352Abstract: The present invention relates to novel human coagulation Factor VII/VIIa proteins having coagulant potential/activity as well as pharmaceutical compositions comprising the proteins, uses thereof, and methods of treatment therewith. In particular, the present invention relates to novel, semi synthetic analogues of human coagulation Factor VII and VIIa (FVII and FVIIa) as well as to a method of their production.Type: GrantFiled: March 30, 2006Date of Patent: October 7, 2008Assignee: Novo Nordisk Healthcare AGInventor: Nils Langeland Johansen
-
Patent number: 7429566Abstract: Use of factor XIII for treating hemophilia B. A patient having hemophilia B is treated by administering factor XIII, generally in conjunction with factor IX.Type: GrantFiled: September 15, 2006Date of Patent: September 30, 2008Assignee: Zymogenetics Inc.Inventors: Jan Öhrström, Lynn Massman Rose, Paul D. Bishop
-
Patent number: 7411039Abstract: The present invention relates to novel human glucagon-like peptide-2 (GLP-2) peptides and human glucagon-like peptide-2 derivatives which have a protracted profile of action as well as polynucleotide constructs encoding such peptides, vectors and host cells comprising and expressing the polynucleotide, pharmaceutical compositions, uses and methods of treatment.Type: GrantFiled: October 14, 2003Date of Patent: August 12, 2008Assignee: Novo Nordisk A/SInventors: Lars Thim, Susanne Bang, Niels Christian Kaarsholm, Anette Sams Nielsen, Nils Langeland Johansen, Kjeld Madsen, Magali Zundel, Peter Thygesen, Birgitte Michelsen
-
Patent number: 7220556Abstract: The cDNA which codes for factor XIIIa has been isolated using a cDNA bank from human placenta and probes constructed on the basis of the amino acid sequence of factor XIIIa peptide fragments. It is possible with this cDNA not only to obtain factor XIIIa by gene manipulation in high purity but also to prepare diagnostic aids which permit the analysis of genetic factor XIIIa defects. Furthermore, it is possible on the basis of the amino acid sequence to prepare antibodies which are suitable for diagnostic aids and antibody columns.Type: GrantFiled: June 2, 1995Date of Patent: May 22, 2007Assignee: ZLB Behring GmbHInventors: Ulrich Grundmann, Egon Amann, Gerd Zettlmeissl
-
Patent number: 7173005Abstract: Peptide sequences capable of binding to insulin and/or insulin-like growth factor receptors with either agonist or antagonist activity and identified from various peptide libraries are disclosed. This invention also identifies at least two different binding sites, which are present on insulin and insulin-like growth factor receptors, and which selectively bind the peptides of this invention. As agonists, the peptides of this invention may be useful for development as therapeutics to supplement or replace endogenous peptide hormones. The antagonist peptides may also be developed as therapeutics.Type: GrantFiled: September 24, 2002Date of Patent: February 6, 2007Assignees: Antyra Inc., Novo Nordisk A/SInventors: Renuka Pillutla, Olga Dedova, Arthur J. Blume, Neil I. Goldstein, Renee Brissette, Pinger Wang, Hao Liu, Ku-Chuan Hsiao, Michael Lennick, Paul Fletcher
-
Patent number: 7153830Abstract: Use of factor XIII for inhibiting the formation of seromas by administering factor XIII. The factor XIII can be administered locally at the site of a wound or surgery or administered systemically. If the factor XIII is administered locally, it can be activated or non-activated and may be administered in conjunction with activated thrombin.Type: GrantFiled: March 16, 2005Date of Patent: December 26, 2006Assignee: ZymoGenetics, Inc.Inventors: Paul D. Bishop, Angelika Grossman
-
Patent number: 7141548Abstract: The present invention provides methods and compositions for preventing hyperinsulinemia that can result from therapeutic administration of growth hormone. The methods are carried out by imposing a restricted high-fat diet and/or by administering one or more drugs that lower serum lipids.Type: GrantFiled: June 4, 2004Date of Patent: November 28, 2006Assignee: Novo Nordisk A/SInventors: Thue Johansen, Kjell Malmlof
-
Patent number: 7125846Abstract: The present invention relates to a composition comprising factor VII or a factor VII-related polypeptide, and factor V or a factor V-related polypeptide, and the use thereof for treating bleeding episodes.Type: GrantFiled: November 8, 2002Date of Patent: October 24, 2006Assignee: Novo Nordisk HealthCare A/GInventor: Rasmus Rojkjaer
-
Patent number: 7115559Abstract: Use of factor XIII for treating coumarin-induced hemorrhage or bleeding. The coumarin may be warfarin or dicoumarol. A patient having coumarin-induced bleeding is treated with factor XIII alone or in conjunction with vitamin K.Type: GrantFiled: September 10, 2002Date of Patent: October 3, 2006Assignee: Zymogenetics Inc.Inventor: Paul D. Bishop
-
Patent number: 7078479Abstract: The present invention relates to a composition comprising factor VII or a factor VII-related polypeptide and alpha2-antiplasmin or an alpha2-antiplasmin-related polypeptide, and the use thereof for treating bleeding episodes.Type: GrantFiled: November 4, 2002Date of Patent: July 18, 2006Assignee: Novo Nordisk HealthCare A/GInventor: Rasmus Rojkjaer
-
Patent number: 7077806Abstract: A method for providing a patient with an analysis result which the patient uses to determine a dosage of a drug for self-administration when the patient is unable to obtain the analysis result themself. The method involves gathering by the patient of information which affects the dosage, forwarding the information to an advisor who analyzes the information to obtain the analysis result, sending the analysis result to the patient, and determining by the patient of the dosage using the analysis result. The information can be gathered by the patient by using a digital camera to photograph an item of food, and the analysis result can be an amount of food. Preferably, the information and analysis result are exchanged via the Internet.Type: GrantFiled: December 19, 2001Date of Patent: July 18, 2006Assignees: Novo Nordisk A/S, Mayo Medical VenturesInventors: Ralf W. Ackermann, Henrik Aspe, Geoffrey S. Gates
-
Patent number: 7015194Abstract: The present invention relates to the use of factor VIIa and TFPI inhibitor in the treatment or prophylaxis of bleeding episodes or coagulative treatment.Type: GrantFiled: October 16, 2002Date of Patent: March 21, 2006Assignee: Novo Nordisk A/SInventor: Marianne Kjalke
-
Patent number: 7008926Abstract: Use of factor XIII for treating the symptoms of thrombocytopenia. A patient having thrombocytopenia, either chemically- or metabolically induced, is treated by administering factor XIII.Type: GrantFiled: February 7, 2002Date of Patent: March 7, 2006Assignee: ZymoGenetics Inc.Inventor: Paul D. Bishop
-
Patent number: 6988613Abstract: A solid, stable composition containing a meiosis activating substance can be prepared by adding a protein or a phosphoglycid in the presence of an atmosphere having a low content of oxygen, for example in vacuo.Type: GrantFiled: February 5, 2002Date of Patent: January 24, 2006Assignee: Novo Nordisk A/SInventors: Tina Meinertz Andersen, Lars Klingberg Muller
-
Patent number: RE39678Abstract: Certain novel sterol derivatives can be used for regulating the meiosis in oocytes and in male germ cells.Type: GrantFiled: June 17, 2004Date of Patent: June 5, 2007Assignees: Novo Nordisk A/S, Schering AktiengesellschaftInventors: Peter Faarup, Frederik Christian Grønvald, Thorsten Blume, Anthony Murray, Jens Breinholt